{"id":547586,"date":"2010-04-30T00:01:38","date_gmt":"2010-04-30T04:01:38","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=76763"},"modified":"2010-04-30T00:01:38","modified_gmt":"2010-04-30T04:01:38","slug":"novartis-buys-alnylam-shares-xconomy-holds-first-ever-health-it-forum-vertex-alumni-spread-throughout-life-sciences-sector-more-boston-area-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/547586","title":{"rendered":"Novartis Buys Alnylam Shares, Xconomy Holds First Ever Health IT Forum, Vertex Alumni Spread Throughout Life Sciences Sector, & More Boston-Area Life Sciences News"},"content":{"rendered":"\n
Roundup<\/a>, Life Sciences<\/a>, Health IT<\/a><\/div>\n

\t\tErin Kutz wrote:<\/strong><\/p>\n

It was a big news week for the intersection of information technology and healthcare, with our first ever forum completely dedicated to the topic, and a few startups in the space nabbing funding. Headlines from big pharma companies rounded it out for us, too.<\/p>\n

—Athenahealth (NASDAQ: ATHN<\/a>), the Watertown, MA-based maker of electronic health records software systems, announced it has hired IBM’s Managed Process Business Services unit<\/a> for IT and administrative support. The deal with IBM (NYSE: IBM<\/a>) will allow Athenahealth to focus on improving the administrative and reimbursement aspects of its products, it said in an announcement.<\/p>\n

—Waltham, MA-based drugmaker Alkermes (NASDAQ: ALKS<\/a>) revealed its royalty rate for exenatide once-weekly (Bydureon), a diabetes drug from Eli Lilly and Amylin Pharmeceuticals that uses Alkermes’ chemistry technology<\/a>. The Waltham company will take in 8 percent of sales of the first 40 million units of the treatment sold per year, which could bring in about $160 million if Bydureon is priced comparably to an existing twice-daily version of exenatide. Alkermes would also take a 5.5 percent royalty rate on sales beyond those first 40 million units.<\/p>\n

—Novartis exercised its option to buy 55,223 more shares of Cambridge, MA-based Alnylam Pharmaceuticals<\/a> (NASDAQ: ALNY<\/a>), for a total of about $1 million. The deal allows pharmaceutical giant Novartis to maintain its 13.4 percent stake in the company, which is developing treatments using RNA interference technology.<\/p>\n

—Charles River Laboratories International plans to buy Chinese R&D services firm WuXi PharmaTech<\/a> for $1.6 billion in cash and common stock, the companies announced on Monday. The $21.25-per-share deal, which is subject to shareholder approval, represents a 28 percent premium over WuXi’s closing stock price on Friday.<\/p>\n

—Ryan caught up with the CEO of Cambridge’s Gene Network Sciences, a startup that’s out to match patients with the drugs that best suit them<\/a>, and help prevent the wasteful spending that results when insurance companies reimburse for treatments that just don’t work. The company formed in 2000 and is widely know for its computer-simulated drug research for big pharma companies, but its new GNS Healthcare subsidiary will attempt to tackle these inefficiencies in the healthcare market.<\/p>\n

—We held our first ever event dedicated solely to exploring the role information technology will play in improving the quality of patient care. Our Healthcare In Transition forum<\/a> featured speakers from …Next Page »<\/a><\/span><\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t\t
\n\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/a>
\n\t\t\t
\n\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Life Sciences, Health IT Erin Kutz wrote: It was a big news week for the intersection of information technology and healthcare, with our first ever forum completely dedicated to the topic, and a few startups in the space nabbing funding. Headlines from big pharma companies rounded it out for us, too. —Athenahealth (NASDAQ: ATHN), […]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7,10],"tags":[],"class_list":["post-547586","post","type-post","status-publish","format-standard","hentry","category-internet","category-news","category-software"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/547586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=547586"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/547586\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=547586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=547586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=547586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}